PHGE

PHGE

USD

BiomX Inc. COmmon Stock

$0.440-0.020 (-4.348%)

即時價格

Healthcare
生物科技
以色列

價格圖表

Loading Chart...

關鍵指標

市場指標
公司基本面
交易統計

市場指標

開盤

$0.460

最高

$0.463

最低

$0.435

交易量

0.13M

公司基本面

市值

11.5M

行業

生物科技

國家

Israel

交易統計

平均交易量

0.13M

交易所

ASE

貨幣

USD

52週範圍

最低 $0.43當前 $0.440最高 $3.86

相關新聞

GlobeNewswire

BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference

NESS ZIONA, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic

查看更多
BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on BiomX, Lowers Price Target to $15

HC Wainwright & Co. analyst Joseph Pantginis maintains BiomX with a Buy and lowers the price target from $21 to $15.

查看更多
HC Wainwright & Co. Maintains Buy on BiomX, Lowers Price Target to $15
GlobeNewswire

BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates

In March 2025, BiomX announced positive topline results of the phase 2 trial evaluating BX211 for the treatment of diabetic foot osteomyelitis (DFO) BX004 Phase 2b study in Cystic Fibrosis (CF) on track to report

查看更多
BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates
GlobeNewswire

BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025

NESS ZIONA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic

查看更多
BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025